CYCC Share Price

Open 4.20 Change Price %
High 4.34 1 Day -0.14 -3.25
Low 4.09 1 Week 0.23 5.84
Close 4.17 1 Month 0.84 25.23
Volume 85585 1 Year 3.58 606.78
52 Week High 9.72
52 Week Low 0.00
CYCC Important Levels
Resistance 2 4.40
Resistance 1 4.31
Pivot 4.20
Support 1 4.03
Support 2 3.94
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
WRES 0.09 0.00%
SIRI 4.41 1.85%
QQQ 116.87 0.23%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
ECTE 0.14 40.00%
BNSO 3.57 31.25%
FRAN 20.01 28.76%
FRAN 20.01 28.76%
FRAN 20.01 28.76%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
CRDS 5.45 25.87%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
IMRS 0.02 -33.33%
More..

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

CYCC Technical Analysis 1.5
As on 6th Dec 2016 CYCC Share Price closed @ 4.17 and we RECOMMEND Buy for LONG-TERM with Stoploss of 3.07 & Sell for SHORT-TERM with Stoploss of 4.69 we also expect STOCK to react on Following IMPORTANT LEVELS.
CYCC Target for December
1st Target up-side 5.33
2nd Target up-side 6.3
3rd Target up-side 7.28
1st Target down-side 2.55
2nd Target down-side 1.58
3rd Target down-side 0.6
CYCC Other Details
Segment EQ
Market Capital 58250856.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cyclacel.com
CYCC Address
CYCC
200 Connell Drive
Suite 1500
Berkeley Heights, NJ 07922
United States
Phone: 908-517-7330
Fax: 866-271-3466
CYCC Latest News
Interactive Technical Analysis Chart Cyclacel Pharmaceuticals, Inc. ( CYCC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cyclacel Pharmaceuticals, Inc.
CYCC Business Profile
Cyclacel Pharmaceuticals, Inc. develops therapies that harness the power of the immune system to treat cancer and other serious illnesses. The Company develops proprietary techniques of antibody engineering to develop antibody-based products for the applications in immunology, oncology, and infectious diseases. Xcyte Therapies is currently conducting Phase I/II clinical trials in hormone-refractory prostate cancer, multiple myeloma and chronic lymphocytic leukemia.